Welcome to our dedicated page for Merus news (Ticker: MRUS), a resource for investors and traders seeking the latest updates and insights on Merus stock.
Merus N.V. (MRUS) generates frequent news as an oncology company focused on full-length human bispecific and trispecific antibody therapeutics, known as Multiclonics®. Its disclosures highlight clinical progress, regulatory designations, corporate transactions and collaboration updates that are relevant to investors and observers of the biotechnology sector.
A central theme in recent Merus news is the development of petosemtamab (MCLA-158), a Biclonics® antibody targeting EGFR and LGR5. Company announcements describe interim data from phase 2 trials in metastatic colorectal cancer, including combinations with FOLFOX and FOLFIRI and monotherapy in later-line settings, as well as data in recurrent or metastatic head and neck squamous cell carcinoma. News releases detail response rates, safety observations and presentations at major scientific meetings such as the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and the American Society of Clinical Oncology Annual Meeting.
Another important news stream concerns regulatory and strategic milestones. Merus has reported that the U.S. FDA granted Breakthrough Therapy Designation to petosemtamab in two head and neck cancer settings, and it has provided updates on phase 3 registration trials in first-line and later-line recurrent or metastatic HNSCC. In parallel, the company issues regular financial and business updates, including quarterly results, capital raises, and details on research collaborations with partners such as Incyte, Eli Lilly, Gilead, Ono and Biohaven.
Recent company announcements also cover the agreed acquisition of Merus by Genmab A/S through a cash tender offer and subsequent back-end transactions. Joint releases and 8-K filings describe the tender offer terms, acceptance levels, change of control and plans for a subsequent offering period. For users following MRUS news, this page offers a consolidated view of clinical, regulatory, financial and corporate developments, including the transition of Merus into an indirect wholly owned subsidiary of Genmab.
Merus N.V. (Nasdaq: MRUS), a company specializing in oncology and developing innovative multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), has announced upcoming presentations at two major investor conferences. CEO Bill Lundberg will present at the William Blair 45th Annual Growth Stock Conference on June 3 at 9:40 a.m. ET and the Jefferies Global Healthcare Conference on June 4 at 3:10 p.m. ET. The presentations will be available via webcast on the company's Investors page, with recordings accessible for a limited time afterward.
- 79% overall survival rate at 12 months - 9 months median progression-free survival - Responses observed across PD-L1 levels - 14 responding patients still on treatment
The treatment combination was generally well-tolerated, with Grade ≥3 treatment-emergent adverse events occurring in 60% of patients. Infusion-related reactions were reported in 38% of patients, mainly during first infusion. The data suggests potential superiority over pembrolizumab monotherapy, positioning petosemtamab as a possible future standard of care in head and neck cancer. Merus expects to share top-line interim readout of phase 3 trials in 2026.
Merus (Nasdaq: MRUS), a biotechnology company specializing in oncology and the development of multispecific antibodies (Biclonics® and Triclonics®), has announced its participation in the BofA Securities 2025 Health Care Conference. CEO Bill Lundberg will engage in a fireside chat on May 15, 2025, at 8:40 a.m. PT/11:40 a.m. ET. The presentation will be available via webcast on the company's Investors webpage, with a recording accessible for a limited time afterward.
Merus N.V. (Nasdaq: MRUS) announced the acceptance of an abstract for presentation at the 2025 ASCO Annual Meeting in Chicago. The presentation will feature updated interim clinical data from their phase 2 trial of petosemtamab with pembrolizumab as first-line treatment for PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).
The poster presentation will include data on the complete 45-patient dataset, building upon previously presented early clinical efficacy and safety data from ASCO 2024. According to CEO Bill Lundberg, petosemtamab shows potential as a first and best-in-class treatment for r/m HNSCC, demonstrating substantial clinical activity superior to historical controls across ORR, PFS, and OS metrics.
The presentation is scheduled for June 2, 2025, and Merus will host an investor conference call on May 22, 2025, to discuss the full data set.
Merus N.V. (Nasdaq: MRUS), a biotechnology company specializing in innovative multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.
The company's President and CEO, Bill Lundberg, M.D., will engage in a fireside chat on Tuesday, April 8, 2025, at 8:45 a.m. ET. Investors and interested parties can access the live webcast through the Investors section of the Merus website, where the presentation recording will remain available for a time following the event.
Merus (NASDAQ: MRUS) announced financial results and business updates for Q4 and full year 2024. Key highlights include the FDA approval of BIZENGRI® for NRG1+ pancreatic adenocarcinoma and NSCLC patients, and two Breakthrough Therapy designations for petosemtamab.
The company is advancing two Phase 3 trials for petosemtamab: LiGeR-HN1 (in combination with pembrolizumab for 1L PD-L1+ r/m HNSCC) and LiGeR-HN2 (monotherapy in 2/3L r/m HNSCC), both expected to be substantially enrolled by year-end 2025. Interim data showed a 67% response rate in 1L HNSCC combination therapy and 36% response rate in 2L+ monotherapy.
Financial position remains strong with $724.0 million in cash, cash equivalents and marketable securities as of December 31, 2024, expected to fund operations into 2028.